To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
1,896 Newest Publications of Future Medicine
rss
News & Views in ... Pharmacogenomics
07-06-2013 | Pharmacogenomics, 2013
Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 853-856.
Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis
07-06-2013 | Huizhe Wu; Hui Kang; Yong Liu; Qinghuan Xiao; Yining Zhang; Mingjun Sun; Duo Liu; Zhe Wang; Haishan ..., Pharmacogenomics, 2013
Aim: To evaluate the association of ABCB1 gene polymorphisms with susceptibility to colorectal cancer (CRC) and clinical outcomes of CRC patients with chemotherapy. Patients & methods: A case–control study was performed on the C3435T, C1236T and G2677T/A polymorphisms in the ABCB1 gene in ...
Research Highlights: Highlights from the latest research in rheumatoid arthritis pharmacogenomics
07-06-2013 | Andrzej Pawlik; Marek Drozdzik, Pharmacogenomics, 2013
Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 857-860.
Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
07-06-2013 | Talitha I Verhoef; William K Redekop; David L Veenstra; Rahber Thariani; Peter A Beltman; Rianne MF van ..., Pharmacogenomics, 2013
Aim: To investigate the cost–effectiveness of pharmacogenetic-guided phenprocoumon dosing versus standard anticoagulation care in Dutch patients with atrial fibrillation. Materials & methods: Using a decision-analytic Markov model, cost–effectiveness of pharmacogenetic-guided therapy versus ...
Practical limitations to estimating heritability in pharmacogenetic studies
07-06-2013 | Kijoung Song; Michael Mosteller; Michael Lawson; Matthew R Nelson, Pharmacogenomics, 2013
Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 851-852.
Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy
07-06-2013 | Sabrina Angelini; Gloria Ravegnini; Jonathan A Fletcher; Francesca Maffei; Patrizia Hrelia, Pharmacogenomics, 2013
Gastrointestinal stromal tumor (GIST) is a well-recognized and now relatively well-understood mesenchymal tumor. Before the imatinib era, the treatment of metastatic GIST was frustrating owing to its refractoriness to conventional chemotherapy and radiotherapy. After a metastatic GIST patient ...
Acknowledgements
07-06-2013 | Pharmacogenomics, 2013
Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 997-997.
Pharmacogenomics of lipid-lowering therapies
07-06-2013 | Miao Hu; Brian Tomlinson, Pharmacogenomics, 2013
Statins are the most widely used group of lipid-lowering drugs and they have been shown to be effective in the prevention of cardiovascular disease, primarily by reducing plasma low-density lipoprotein cholesterol concentrations and possibly through other pleiotropic effects. However, there ...
Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists
07-06-2013 | Rachel Mills; Susanne B Haga, Pharmacogenomics, 2013
One of the basic questions in the early uses of pharmacogenetic (PGx) testing revolves around the clinical delivery of testing. Because multiple health professionals may play a role in the delivery of PGx testing, various clinical delivery models have begun to be studied. We propose that a ...
High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6
07-06-2013 | Greyson P Twist; Roger Gaedigk; J Steven Leeder; Andrea Gaedigk, Pharmacogenomics, 2013
High-resolution melt (HRM) analysis using ‘release-on-demand’ dyes, such as EvaGreen® has the potential to resolve complex genotypes in situations where genotype interpretation is complicated by the presence of pseudogenes or allelic variants in close proximity to the locus of interest. We ...
Netmeeting
